PURPOSE: The X-ray repair cross-complementing Group 1 (XRCC1) protein is involved mainly in the base excision repair of the DNA repair process. This study examined the association of 3 polymorphisms (codon 194, 280, and 399) of XRCC1 and lung cancer in terms of whether or not these polymorphisms have an effect on the survival of lung cancer patients who have received radiotherapy. METHODS AND MATERIALS: Between January 2000 and April 2004, 229 lung cancer patients with non-small-cell lung cancer in Stages I-III were enrolled. Genotyping was performed by single base primer extension assay using the SNP-IT Kit with genomic DNA samples from all patients. The haplotype of the XRCC1 polymorphisms was estimated by PHASE version 2.1. RESULTS: The patients consisted of 191 (83.4%) males and 38 (16.6%) females with a median age of 62 (range, 26-88 years). Sixty percent of the patients were included in Stage I-IIIa. The median progression-free and overall survival was 13 months and 16 months, respectively. The XRCC1 codon 194, histology, and stage were shown to be significant predictors of the progression-free survival. The 6 haplotypes among the XRCC1 polymorphisms (194, 280, and 399) were estimated by PHASE v.2.1. The patients with haplotype pairs other than the homozygous TGG haplotype pairs survived significantly longer (p = 0.04). CONCLUSIONS: Polymorphisms of XRCC1 have an effect on the survival of lung cancer patients treated with radiotherapy, and this effect seems to be more significant after the haplotype pairs are considered.
PURPOSE: The X-ray repair cross-complementing Group 1 (XRCC1) protein is involved mainly in the base excision repair of the DNA repair process. This study examined the association of 3 polymorphisms (codon 194, 280, and 399) of XRCC1 and lung cancer in terms of whether or not these polymorphisms have an effect on the survival of lung cancerpatients who have received radiotherapy. METHODS AND MATERIALS: Between January 2000 and April 2004, 229 lung cancerpatients with non-small-cell lung cancer in Stages I-III were enrolled. Genotyping was performed by single base primer extension assay using the SNP-IT Kit with genomic DNA samples from all patients. The haplotype of the XRCC1 polymorphisms was estimated by PHASE version 2.1. RESULTS: The patients consisted of 191 (83.4%) males and 38 (16.6%) females with a median age of 62 (range, 26-88 years). Sixty percent of the patients were included in Stage I-IIIa. The median progression-free and overall survival was 13 months and 16 months, respectively. The XRCC1 codon 194, histology, and stage were shown to be significant predictors of the progression-free survival. The 6 haplotypes among the XRCC1 polymorphisms (194, 280, and 399) were estimated by PHASE v.2.1. The patients with haplotype pairs other than the homozygous TGG haplotype pairs survived significantly longer (p = 0.04). CONCLUSIONS: Polymorphisms of XRCC1 have an effect on the survival of lung cancerpatients treated with radiotherapy, and this effect seems to be more significant after the haplotype pairs are considered.
Authors: Z Sun; J Chen; J Aakre; R S Marks; Y Y Garces; R Jiang; O Idowu; J M Cunningham; Y Liu; V S Pankratz; P Yang Journal: Ann Oncol Date: 2010-05-03 Impact factor: 32.976
Authors: Mei-Kim Ang; Mihir R Patel; Xiao-Ying Yin; Sneha Sundaram; Karen Fritchie; Ni Zhao; Yufeng Liu; Alex J Freemerman; Matthew D Wilkerson; Vonn Walter; Mark C Weissler; William W Shockley; Marion E Couch; Adam M Zanation; Trevor Hackman; Bhishamjit S Chera; Stephen L Harris; C Ryan Miller; Leigh B Thorne; Michele C Hayward; William K Funkhouser; Andrew F Olshan; Carol G Shores; Liza Makowski; D Neil Hayes Journal: Clin Cancer Res Date: 2011-09-09 Impact factor: 12.531
Authors: Sharon R Pine; Leah E Mechanic; Stefan Ambs; Elise D Bowman; Stephen J Chanock; Christopher Loffredo; Peter G Shields; Curtis C Harris Journal: J Natl Cancer Inst Date: 2007-09-11 Impact factor: 13.506
Authors: S Sakano; T Wada; H Matsumoto; S Sugiyama; R Inoue; S Eguchi; H Ito; C Ohmi; H Matsuyama; K Naito Journal: Br J Cancer Date: 2006-08-01 Impact factor: 7.640
Authors: Xianglin Yuan; Qingyi Wei; Ritsuko Komaki; Zhensheng Liu; Ju Yang; Susan L Tucker; Ting Xu; John V Heymach; Charles Lu; James D Cox; Zhongxing Liao Journal: PLoS One Date: 2013-06-19 Impact factor: 3.240